Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/19135
Title: Outcome of Epithelial Ovarian Cancer Time for Strategy Trials to Resolve the Problem of Optimal Timing of Surgery
Authors: Van de Putte, Gregg
OBEN, Jolien 
PRENEN, Leen 
Schobbens, Jean Christophe
Vlasselaer, Jos
Van Holsbeke, Caroline
DEBROCK, Guy 
Van Eycken, Peter
DE JONGE, Eric 
Issue Date: 2015
Publisher: LIPPINCOTT WILLIAMS & WILKINS
Source: INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 25 (6), p. 993-999
Abstract: Introduction The standard treatment of ovarian cancer is the combination of debulking surgery and chemotherapy. There is an ongoing discussion on which treatment is best: primary debulking surgery (PDS) or neoadjuvant chemotherapy with interval debulking (NACT-IDS). Even a large randomized trial has not settled this issue. We examined whether comparing a specified treatment protocol would not be a more logical approach to answer this type of discussions. Methods A retrospective study of 142 consecutively treated patients according to a fixed protocol between 2000 and 2012 was conducted. Disease-free survival and overall survival were calculated by univariate and multivariate analyses for the whole group and for advanced stages separately. Specific differences between PDS and NACT-IDS were studied. Comparison of results from large databases was made. Results Disease-free survival and overall 5-year survival for the whole group were 35% and 50%. For the advanced stages, disease-free survival and overall 5-year survival were 14% and 36%, with a median disease-free and overall survival of 16 and 44 months. Of the 98 women with advanced ovarian carcinoma, 54% of operable patients underwent PDS and 44% underwent NACT-IDS. More patients in the PDS group were optimally (<1 cm) debulked: 80% vs 71%. There was no significant difference in survival between PDS or NACT-IDS. Optimally debulked patients had a significant better overall survival in multivariate analysis with a hazard ratio of 2.1. Discussion Outcome of treatment according to a fixed protocol with a mixture of PDS and NACT-IDS was similar to results from large databases. We hypothesize that comparison of a specific strategy may yield more useful results than awaiting the perfect randomized trial.
Notes: [Van de Putte, Gregg; Oben, Jolien; Schobbens, Jean Christophe; Vlasselaer, Jos; Van Holsbeke, Caroline; de Jonge, Eric] Ziekenhuis Oost Limburg, Dept Gynecol, Genk, Belgium. [Prenen, Leen] Univ Hasselt, Interuniv Inst Biostat & Stat Bioinformat, Diepenbeek, Belgium. [Debrock, Guy] Ziekenhuis Oost Limburg, Dept Oncol, Genk, Belgium. [Van Eycken, Peter] Ziekenhuis Oost Limburg, Dept Pathol, Genk, Belgium.
Keywords: Ovarian carcinoma; Surgery; Neoadjuvant chemotherapy; Survival; Strategy;ovarian carcinoma; surgery; neoadjuvant chemotherapy; survival; strategy
Document URI: http://hdl.handle.net/1942/19135
ISSN: 1048-891X
e-ISSN: 1525-1438
DOI: 10.1097/IGC.0000000000000461
ISI #: 000357286900008
Rights: © 2015 by the International Gynecologic Cancer Society and the European Society of Gynaecological Oncology.
Category: A1
Type: Journal Contribution
Validations: ecoom 2016
Appears in Collections:Research publications

Files in This Item:
File Description SizeFormat 
Outcome_of_Epithelial_Ovarian_Cancer__Time_for.8.pdf
  Restricted Access
212.67 kBAdobe PDFView/Open    Request a copy
Show full item record

SCOPUSTM   
Citations

2
checked on Sep 3, 2020

WEB OF SCIENCETM
Citations

2
checked on May 22, 2022

Page view(s)

22
checked on May 26, 2022

Download(s)

10
checked on May 26, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.